JP2014240408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014240408A5 JP2014240408A5 JP2014158170A JP2014158170A JP2014240408A5 JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5 JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- eosinophilic
- prednisone
- treatment
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims description 8
- 210000003979 eosinophil Anatomy 0.000 claims description 5
- 150000003431 steroids Chemical class 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 10
- 229960004618 prednisone Drugs 0.000 claims 10
- 102000000743 Interleukin-5 Human genes 0.000 claims 7
- 108010002616 Interleukin-5 Proteins 0.000 claims 7
- 230000003472 neutralizing effect Effects 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 208000030852 Parasitic disease Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000015768 polyposis Diseases 0.000 claims 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000028185 Angioedema Diseases 0.000 claims 1
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 208000006968 Helminthiasis Diseases 0.000 claims 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 claims 1
- 208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 241000243981 Onchocerca Species 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 201000009323 chronic eosinophilic pneumonia Diseases 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 206010014665 endocarditis Diseases 0.000 claims 1
- 206010057271 eosinophilic colitis Diseases 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 1
- 201000001561 eosinophilic gastritis Diseases 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 208000001797 obstructive sleep apnea Diseases 0.000 claims 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4036308P | 2008-03-28 | 2008-03-28 | |
| US61/040,363 | 2008-03-28 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502090A Division JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016214438A Division JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014240408A JP2014240408A (ja) | 2014-12-25 |
| JP2014240408A5 true JP2014240408A5 (Direct) | 2016-02-18 |
| JP6069267B2 JP6069267B2 (ja) | 2017-02-01 |
Family
ID=41114741
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502090A Active JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
| JP2014158170A Active JP6069267B2 (ja) | 2008-03-28 | 2014-08-01 | 処置方法 |
| JP2016214438A Active JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
| JP2018238018A Pending JP2019065029A (ja) | 2008-03-28 | 2018-12-20 | 処置方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502090A Active JP5917143B2 (ja) | 2008-03-28 | 2009-03-27 | 処置方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016214438A Active JP6457463B2 (ja) | 2008-03-28 | 2016-11-01 | 処置方法 |
| JP2018238018A Pending JP2019065029A (ja) | 2008-03-28 | 2018-12-20 | 処置方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9834600B2 (Direct) |
| EP (1) | EP2274009B1 (Direct) |
| JP (4) | JP5917143B2 (Direct) |
| KR (1) | KR20100134702A (Direct) |
| CN (1) | CN102026660A (Direct) |
| AU (1) | AU2009228163B2 (Direct) |
| BR (1) | BRPI0910854A2 (Direct) |
| CA (1) | CA2719786A1 (Direct) |
| EA (1) | EA201071137A1 (Direct) |
| ES (1) | ES2441945T3 (Direct) |
| IL (1) | IL208354A0 (Direct) |
| MX (1) | MX2010010667A (Direct) |
| WO (1) | WO2009120927A2 (Direct) |
| ZA (1) | ZA201006648B (Direct) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008224844B2 (en) | 2007-03-14 | 2012-08-09 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
| EA201071137A1 (ru) | 2008-03-28 | 2011-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения |
| JP2012500283A (ja) | 2008-08-19 | 2012-01-05 | ノップ ニューロサイエンシーズ、インク． | （ｒ）−プラミペキソールを使用した組成物並びにその方法 |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| DE12722942T1 (de) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | Freisetzung und formulierung von manipulierten nukleinsäuren |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| SI3682905T1 (sl) | 2011-10-03 | 2022-04-29 | Modernatx, Inc. | Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe |
| US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| HK1206601A1 (en) | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
| SI2922554T1 (sl) | 2012-11-26 | 2022-06-30 | Modernatx, Inc. | Terminalno modificirana RNA |
| US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
| SI3838271T1 (sl) | 2013-07-12 | 2025-12-31 | Areteia Therapeutics, Inc. | Zdravljenje povišanih ravni eozinofilcev in/ali bazofilcev |
| PT3033081T (pt) | 2013-08-13 | 2021-06-01 | Knopp Biosciences Llc | Composições e métodos para o tratamento da urticária crónica |
| AU2014306683B2 (en) | 2013-08-13 | 2017-10-12 | Knopp Biosciences Llc | Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
| SI3191513T1 (sl) | 2014-09-08 | 2020-12-31 | Cephalon, Inc. | Uporaba reslizumaba za zdravljenje zmerne do hude eozinofilne astme |
| AU2016311385C1 (en) | 2015-08-24 | 2019-08-22 | Glaxosmithkline Intellectual Property (No.2) Limited | Biopharmaceutical compositions |
| CN117018190A (zh) | 2017-05-26 | 2023-11-10 | 葛兰素史密斯克莱知识产权发展有限公司 | 生物制药组合物和相关方法 |
| KR20230067604A (ko) * | 2020-08-05 | 2023-05-16 | 아레테이아 테라퓨틱스, 인코포레이티드 | 중등도 내지 중증 천식의 치료를 위한 덱스프라미펙솔의 용도 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8800397D0 (en) * | 1988-01-08 | 1988-02-10 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US5096704A (en) * | 1988-11-03 | 1992-03-17 | Schering Corporation | Method of treating eosinophilia |
| WO1990004979A2 (en) | 1988-11-03 | 1990-05-17 | Schering Corporation | Method of preventing or reducing eosinophilia |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0533006A1 (en) * | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
| KR100254759B1 (ko) | 1992-01-23 | 2000-05-01 | 플레믹 크리스티안 | 단량체 및 이량체 항체-단편 융합 단백질 |
| HUT67943A (en) | 1992-02-06 | 1995-05-29 | Schering Corp | Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5 |
| JPH06141885A (ja) | 1992-11-05 | 1994-05-24 | Chemo Sero Therapeut Res Inst | モノクローナル抗体 |
| AU1289795A (en) | 1993-11-19 | 1995-06-06 | Baylor College Of Medicine | Monoclonal antibodies specific for human interleukin-5 |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| MX9704779A (es) | 1994-12-23 | 1997-09-30 | Smithkline Beecham Corp | Antagonistas de interleukina-5 recombinante, utiles en la preparacion de composiciones para el tratamiento de perturbaciones mediadas por interleukina-5. |
| US5783184A (en) | 1994-12-23 | 1998-07-21 | Smithkline Beecham Corporation | Method for treatment and diagnosis of IL-5 mediated disorders |
| US7399837B2 (en) * | 1995-12-22 | 2008-07-15 | Smithkline Beecham Corporation | Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
| US6248723B1 (en) * | 1997-06-10 | 2001-06-19 | National Jewish Medical And Research Center | Method for treatment of inflammatory disease |
| PL340606A1 (en) * | 1997-10-22 | 2001-02-12 | Jens Ponikau | Methods of and materials for treating and preventing mucositis |
| WO2001012646A1 (en) | 1999-08-19 | 2001-02-22 | Smithkline Beecham Corporation | Sialoadhesin factor-1 agonist and antagonist antibodies |
| US20030017169A1 (en) * | 2000-12-29 | 2003-01-23 | Sidney Pestka | Controlled release systems for polymers |
| DE60328195D1 (de) * | 2002-03-29 | 2009-08-13 | Schering Corp | Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen |
| US7339507B1 (en) * | 2006-09-13 | 2008-03-04 | Jiun-In Guo | Device for video decoding |
| EP2111237B1 (en) * | 2006-12-11 | 2015-03-18 | BRACCO IMAGING S.p.A. | Fibrin-binding peptides and conjugates thereof |
| JP2010526087A (ja) | 2007-04-30 | 2010-07-29 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 抗ｉｌ−５抗体を投与するための方法 |
| US20090035216A1 (en) * | 2007-08-03 | 2009-02-05 | Biomonitor Aps | Method for determining in vivo biopharmaceutical concentration or bioavailability |
| EA201071137A1 (ru) | 2008-03-28 | 2011-04-29 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Способы лечения |
| US8926631B2 (en) | 2010-08-06 | 2015-01-06 | MoMelan Technologies, Inc. | Methods for preparing a skin graft without culturing or use of biologics |
| EP2672986B1 (en) | 2011-02-09 | 2020-03-18 | GlaxoSmithKline LLC | Lyophilized formulations |
-
2009
- 2009-03-27 EA EA201071137A patent/EA201071137A1/ru unknown
- 2009-03-27 US US12/935,038 patent/US9834600B2/en active Active
- 2009-03-27 KR KR1020107024046A patent/KR20100134702A/ko not_active Withdrawn
- 2009-03-27 WO PCT/US2009/038509 patent/WO2009120927A2/en not_active Ceased
- 2009-03-27 CA CA2719786A patent/CA2719786A1/en not_active Abandoned
- 2009-03-27 JP JP2011502090A patent/JP5917143B2/ja active Active
- 2009-03-27 CN CN2009801176573A patent/CN102026660A/zh active Pending
- 2009-03-27 MX MX2010010667A patent/MX2010010667A/es not_active Application Discontinuation
- 2009-03-27 EP EP09725345.4A patent/EP2274009B1/en not_active Revoked
- 2009-03-27 ES ES09725345.4T patent/ES2441945T3/es active Active
- 2009-03-27 AU AU2009228163A patent/AU2009228163B2/en not_active Ceased
- 2009-03-27 BR BRPI0910854A patent/BRPI0910854A2/pt not_active IP Right Cessation
-
2010
- 2010-09-16 ZA ZA2010/06648A patent/ZA201006648B/en unknown
- 2010-09-21 IL IL208354A patent/IL208354A0/en unknown
-
2014
- 2014-08-01 JP JP2014158170A patent/JP6069267B2/ja active Active
-
2016
- 2016-11-01 JP JP2016214438A patent/JP6457463B2/ja active Active
-
2017
- 2017-11-06 US US15/804,104 patent/US20180057582A1/en not_active Abandoned
-
2018
- 2018-12-20 JP JP2018238018A patent/JP2019065029A/ja active Pending
-
2019
- 2019-09-19 US US16/575,903 patent/US11325972B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014240408A5 (Direct) | ||
| JP2011516422A5 (Direct) | ||
| JP2015529225A5 (Direct) | ||
| JP2016528247A5 (Direct) | ||
| JP2018184417A5 (Direct) | ||
| EP2433650A3 (en) | Administration of anti-CD3 antibodies in the treatment of autoimmune diseases | |
| JP2016515124A5 (Direct) | ||
| JP2013538553A5 (Direct) | ||
| JP2015007098A5 (Direct) | ||
| JP2013527233A5 (Direct) | ||
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| JP2019533646A5 (Direct) | ||
| JP2017160178A5 (Direct) | ||
| HRP20231015T1 (hr) | Upotreba antagonista il-13 u liječenju atopičnog dermatitisa | |
| JP2012046518A5 (Direct) | ||
| JP2014530226A5 (Direct) | ||
| JP2016536361A5 (Direct) | ||
| MY197558A (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| GR1007832B (el) | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" | |
| JP2015505564A5 (Direct) | ||
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2016094424A5 (Direct) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2016512817A5 (Direct) | ||
| JP2018512402A5 (Direct) |